This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wang, H. Articles by Lin, D. Search for Related Content PubMed PubMed Citation Articles by Wang, H. Articles by Lin, D.

Substantial Reduction in Risk of Lung Adenocarcinoma Associated with Genetic Polymorphism in CYP2A13, the Most Active Cytochrome P450 for the Metabolic Activation of Tobacco-Specific Carcinogen NNK

¹ Laboratory of Systems Biology, Beijing Institute of Radiation Medicine, and Chinese National Human Genome Center at Beijing;
² Department of Etiology and Carcinogenesis, Cancer Institute, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Cytochrome P450 2A13 (CYP2A13), an enzyme expressed predominantly in the human respiratory tract, exhibits high efficiency in the metabolic activation of tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). A CT transition in the CYP2A13 gene causes Arg257Cys amino acid substitution and, thus, results in a significantly reduced activity toward NNK and other substrates. In this case-control study, we genotyped 724 patients with lung cancer and 791 controls for this polymorphism to examine the hypothesis that the variant CYP2A13 may have impact on risk of lung cancer in relation to tobacco smoking. A gene deletion polymorphism (CYP2A6*4) in CYP2A6, another enzyme involved in the metabolic activation of tobacco nitrosamines, was also analyzed as a comparison. We found that, compared with the CC genotype, the variant CYP2A13 genotype (CT + TT) was associated with substantially reduced risk for lung adenocarcinoma [odds ratio (OR), 0.41; 95% confidence interval (CI), 0.23–0.71], but not squamous cell carcinoma (OR, 0.86; 95% CI, 0.57–1.29) or other types of lung cancer (OR, 0.58; 95% CI, 0.32–1.09). Stratification analysis shows that the reduced risk of lung adenocarcinoma related to the variant CYP2A13 genotype was limited to smokers, especially light smokers (OR, 0.23; 95% CI, 0.08–0.68) but not nonsmokers or heavy smokers. No association was observed between CYP2A6 genotype and risk of lung cancer. Our results demonstrate for the first time that the variant CYP2A13 allele is associated with reduced risk of lung adenocarcinoma, suggesting the role of NNK-CYP2A13 interaction as a causative factor for the cancer.

This article has been cited by other articles:

				M. N. Timofeeva, S. Kropp, W. Sauter, L. Beckmann, A. Rosenberger, T. Illig, B. Jager, K. Mittelstrass, H. Dienemann, The LUCY-Consortium, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences Carcinogenesis, July 1, 2009; 30(7): 1161 - 1169. [Abstract] [Full Text] [PDF]

				C. Wu, Z. Hu, D. Yu, L. Huang, G. Jin, J. Liang, H. Guo, W. Tan, M. Zhang, J. Qian, et al. Genetic Variants on Chromosome 15q25 Associated with Lung Cancer Risk in Chinese Populations Cancer Res., June 15, 2009; 69(12): 5065 - 5072. [Abstract] [Full Text] [PDF]

				N. M. DeVore, B. D. Smith, J. L. Wang, G. H. Lushington, and E. E. Scott Key Residues Controlling Binding of Diverse Ligands to Human Cytochrome P450 2A Enzymes Drug Metab. Dispos., June 1, 2009; 37(6): 1319 - 1327. [Abstract] [Full Text] [PDF]

				J. D'Agostino, X. Zhang, H. Wu, G. Ling, S. Wang, Q.-Y. Zhang, F. Liu, and X. Ding Characterization of CYP2A13*2, a Variant Cytochrome P450 Allele Previously Found to Be Associated with Decreased Incidences of Lung Adenocarcinoma in Smokers Drug Metab. Dispos., November 1, 2008; 36(11): 2316 - 2323. [Abstract] [Full Text] [PDF]

				X. Zhang, J. D'Agostino, H. Wu, Q.-Y. Zhang, L. von Weymarn, S. E. Murphy, and X. Ding CYP2A13: Variable Expression and Role in Human Lung Microsomal Metabolic Activation of the Tobacco-Specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 570 - 578. [Abstract] [Full Text] [PDF]

				P. J. Brown, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey Analysis of CYP2A Contributions to Metabolism of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone in Human Peripheral Lung Microsomes Drug Metab. Dispos., November 1, 2007; 35(11): 2086 - 2094. [Abstract] [Full Text] [PDF]

				B. D. Smith, J. L. Sanders, P. R. Porubsky, G. H. Lushington, C. D. Stout, and E. E. Scott Structure of the Human Lung Cytochrome P450 2A13 J. Biol. Chem., June 8, 2007; 282(23): 17306 - 17313. [Abstract] [Full Text] [PDF]

				G. Ling, Y. Wei, and X. Ding Transcriptional Regulation of Human CYP2A13 Expression in the Respiratory Tract by CCAAT/Enhancer Binding Protein and Epigenetic Modulation Mol. Pharmacol., March 1, 2007; 71(3): 807 - 816. [Abstract] [Full Text] [PDF]

				S. Razani-Boroujerdi and M. L. Sopori Early Manifestations of NNK-Induced Lung Cancer: Role of Lung Immunity in Tumor Susceptibility Am. J. Respir. Cell Mol. Biol., January 1, 2007; 36(1): 13 - 19. [Abstract] [Full Text] [PDF]

				S.-L. Wang, X.-Y. He, J. Shen, J.-S. Wang, and J.-Y. Hong The Missense Genetic Polymorphisms of Human CYP2A13: Functional Significance in Carcinogen Activation and Identification of A Null Allelic Variant Toxicol. Sci., November 1, 2006; 94(1): 38 - 45. [Abstract] [Full Text] [PDF]

				C. Chao, Z.-F. Zhang, J. Berthiller, P. Boffetta, and M. Hashibe NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Pro187Ser Polymorphism and the Risk of Lung, Bladder, and Colorectal Cancers: a Meta-analysis. Cancer Epidemiol. Biomarkers Prev., May 1, 2006; 15(5): 979 - 987. [Abstract] [Full Text] [PDF]

				J. H. Kim, H. Kim, K. Y. Lee, K.-H. Choe, J.-S. Ryu, H. I. Yoon, S. W. Sung, K.-Y. Yoo, and Y.-C. Hong Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk Hum. Mol. Genet., April 1, 2006; 15(7): 1181 - 1186. [Abstract] [Full Text] [PDF]

				J. Hukkanen, P. Jacob III, and N. L. Benowitz Metabolism and Disposition Kinetics of Nicotine Pharmacol. Rev., March 1, 2005; 57(1): 79 - 115. [Abstract] [Full Text] [PDF]

				L. B. von Weymarn, Q.-Y. Zhang, X. Ding, and P. F. Hollenberg Effects of 8-methoxypsoralen on cytochrome P450 2A13 Carcinogenesis, March 1, 2005; 26(3): 621 - 629. [Abstract] [Full Text] [PDF]

				Z. Bao, X.-Y. He, X. Ding, S. Prabhu, and J.-Y. Hong METABOLISM OF NICOTINE AND COTININE BY HUMAN CYTOCHROME P450 2A13 Drug Metab. Dispos., February 1, 2005; 33(2): 258 - 261. [Abstract] [Full Text] [PDF]

				X.-Y. He, J. Shen, X. Ding, A. Y. H. Lu, and J.-Y. Hong IDENTIFICATION OF CRITICAL AMINO ACID RESIDUES OF HUMAN CYP2A13 FOR THE METABOLIC ACTIVATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE, A TOBACCO-SPECIFIC CARCINOGEN Drug Metab. Dispos., December 1, 2004; 32(12): 1516 - 1521. [Abstract] [Full Text] [PDF]

				M. Fujieda, H. Yamazaki, T. Saito, K. Kiyotani, M. A. Gyamfi, M. Sakurai, H. Dosaka-Akita, Y. Sawamura, J. Yokota, H. Kunitoh, et al. Evaluation of CYP2A6 genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers Carcinogenesis, December 1, 2004; 25(12): 2451 - 2458. [Abstract] [Full Text] [PDF]

				X. Zhang, M. Caggana, T. L. Cutler, and X. Ding Development of a Real-Time Polymerase Chain Reaction-Based Method for the Measurement of Relative Allelic Expression and Identification of CYP2A13 Alleles with Decreased Expression in Human Lung J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 373 - 381. [Abstract] [Full Text] [PDF]

				G. Ling, C. R. Hauer, R. M. Gronostajski, B. T. Pentecost, and X. Ding Transcriptional Regulation of Rat CYP2A3 by Nuclear Factor 1: IDENTIFICATION OF A NOVEL NFI-A ISOFORM, AND EVIDENCE FOR TISSUE-SELECTIVE INTERACTION OF NFI WITH THE CYP2A3 PROMOTER IN VIVO J. Biol. Chem., July 2, 2004; 279(27): 27888 - 27895. [Abstract] [Full Text] [PDF]